Kannoli Pharma (“Kannoli”), a brand owned by Alkannoli L.D.A., is a new ’disruptor‘ in the nascent but fast growing European Medical Cannabis industry, with an overaching strategy to grow, extract and manufacture EU-GMP certified medical cannabis products, initially for the EU market.
Kannoli’s expandable production facility will be a stand out environmental project, addressing the need for the production of consistent, high quality, and innovative cannabis products for the EU healthcare market.
Medical Cannabis extracts and applications are used in the treatment of a wide range of
diseases and symptoms, including cancer, chronic pain, depression, arthritis, diabetes,
glaucoma, migraines, epilepsy, multiple sclerosis, etc.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Rua Do Campo, Sintra,2710-476,portugal
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://kannolipharma.com/
- HQ
- Sintra
Kannoli Pharma Questions
Kannoli Pharma's website is https://kannolipharma.com/
Kannoli Pharma's LinkedIn profile is https://pt.linkedin.com/company/kannoli-pharma
Kannoli Pharma has
3 employees.
View email and phone details for 3
employees at Kannoli Pharma.
Kannoli Pharma's industry is
Pharmaceutical Manufacturing
Kannoli Pharma's top competitors are
Salvat,
Sainshand Salkhin Park Llc,
Cann10 Portugal,
Teva Pharmaceuticals,
Lumino,
Master Med Cannabis,
Euro Khan Llc,
Cannthyrso,
Norgine,
Cbd Portugal.
Kannoli Pharma's categories are Pharmaceutical Manufacturing
Kannoli Pharma's founding year is 2020
